First Tracks Biotherapeutics (TRAX) — Long-term Investment Intensity
First Tracks Biotherapeutics (TRAX) has a Long-term Investment Intensity of 8.0% as of December 2024. Long-term investments of $35.47 Million represent 8.0% of total assets of $441.89 Million. A higher ratio indicates a company with significant capital committed to long-duration strategic positions. See First Tracks Biotherapeutics (TRAX) shareholders funds for net asset value and shareholders' equity analysis.
LT Investment Intensity
Long-term Investments
Total Assets
Country
First Tracks Biotherapeutics Long-term Investment Intensity (2023–2024)
This chart shows how First Tracks Biotherapeutics's Long-term Investment Intensity has evolved across 2 annual periods from 2023 to 2024. As of December 2024, the intensity stands at 8.0%, reflecting long-term investments of $35.47 Million against total assets of $441.89 Million USD. Also explore balance sheet size of First Tracks Biotherapeutics for the complete picture of this company's asset base.
Annual Long-term Investment Intensity for First Tracks Biotherapeutics (2023–2024)
The table below presents the year-by-year Long-term Investment Intensity for First Tracks Biotherapeutics from 2023 to 2024, covering 2 annual filings. Each row shows total assets, long-term investments, the intensity percentage, and the change in percentage points compared to the prior year. For market capitalisation and broader financial context, see First Tracks Biotherapeutics (TRAX) total market value.
| Year | LT Investment Intensity | LT Investments (USD) | Total Assets | Change (pp) |
|---|---|---|---|---|
| 2024 | 8.0% | $35.47 Million | $441.89 Million | ▲ +1.9 pp |
| 2023 | 6.1% | $27.03 Million | $444.11 Million | — |